Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432094 · ClinicalTrials.gov registry record · Phase 2
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00432094 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 23 participants.
The verdict
NCT00432094, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival. PURPOSE: Because prior investigations in GCT suggest that a subset of high risk or relapsed patients may be cured with sequential cycles of high dose chemotherapy and AuSCT, we propose investigating how well non-cross resistant conditioning regimens work in treating patients with relapsed or high risk GCT.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG etoposide
- DRUG ifosfamide
- DRUG thiotepa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-12-19 |
| Est. Completion | 2021-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00432094
The ClinicalTrials.gov registry entry for NCT00432094 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00432094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00432094 about?
NCT00432094 is a clinical study titled "Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors". RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cel...
What is the current status of trial NCT00432094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2006-12-19. Estimated completion is 2021-03.
What interventions are being tested in trial NCT00432094?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), etoposide (DRUG), ifosfamide (DRUG), thiotepa (DRUG).
Who is sponsoring clinical trial NCT00432094?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.